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Background: The most prevalent form of bone cancer is osteosarcoma (OS), which is associated with poor prognosis in case of
metastases formation. Mice harbouring liver kinase B1 (LKB1þ / ) develop osteoblastoma-like tumours. Therefore, we asked
whether loss of LKB1 gene has a role in the pathogenesis of human OS.
Methods: Osteosarcomas (n¼ 259) were screened for LKB1 and sirtuin 1 (SIRT1) protein expression using immunohistochemistry
and western blot. Those cases were also screened for LKB1 genetic alterations by next-generation sequencing, Sanger
sequencing, restriction fragment length polymorphism and fluorescence in situ hybridisation approaches. We studied LKB1
protein degradation through SIRT1 expression. MicroRNA expression investigations were also conducted to identify the
microRNAs involved in the SIRT1/LKB1 pathway.
Results: Forty-one per cent (106 out of 259) OS had lost LKB1 protein expression with no evident genetic anomalies. We obtained
evidence that SIRT1 impairs LKB1 protein stability, and that SIRT1 depletion leads to accumulation of LKB1 in OS cell lines
resulting in growth arrest. Further investigations revealed the role of miR-204 in the regulation of SIRT1 expression, which impairs
LKB1 stability.
Conclusions: We demonstrated the involvement of sequential regulation of miR-204/SIRT1/LKB1 in OS cases and showed a
mechanism for the loss of expression of LKB1 tumour suppressor in this malignancy.
Osteosarcoma (OS) is the most common non-haematopoietic,
primary malignant skeletal neoplasm diagnosed in adolescents
and the second leading cause of cancer-related fatalities within
this age group. It is the eighth most common form of child-
hood cancer, representing 2.4% of all malignancies, and B20% of
all bone cancers (Ottaviani and Jaffe, 2009). Approximately 150
new cases of OS are diagnosed in the United Kingdom
annually, and this incidence is similar to that seen in the western
world (WB) (Statistics and outlook for Bone Cancer;
www.cancerresearchuk.org). Despite aggressive therapeutic man-
agement, which includes neoadjuvant chemotherapy and surgery,
30–40% of patients die within 5 years of diagnosis (Longhi et al,
2006; Ottaviani and Jaffe, 2009). Several studies have confirmed the
complexity and high level of heterogeneity of OS genomes with
complex karyotypes (Chen et al, 2014; Kovac et al, 2015; Lorenz
et al, 2016). Combined genomic and transcriptomic analysis
revealed extensive transcript fusion including PMP22-ELOVL5
gene fusion, recurrent rearrangements in RB1, MTAP/CDKN2A
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andMDM2 genes and also frequent TP53 aberrations (Lorenz et al,
2016). Furthermore, in paediatric OS whole-exome sequencing
identified TP53 gene alterations as well as recurrent somatic
alterations in the genes RB1, ATRX and DLG2 in a significant
number of tumours (Kovac et al, 2015).
Germline mutations in LKB1 cause Peutz-Jegher Syndrome, a
rare disorder predisposing to cancer and multiple gastrointestinal
hamartomatous polyps (Sanchez-Cespedes, 2007; Takeda et al,
2007a). Loss of heterozygosity of LKB1 wild-type allele has been
reported in 50% of tumours (gastrointestinal tract, pancreas,
cervix, ovary and breast) from patients with germline mutations
(Giardiello et al, 1987; Boardman et al, 1998; Ylikorkala et al, 1999;
Momcilovic and Shackelford, 2015). Loss of LKB1 has also been
reported to induce resistance to TRAIL-mediated apoptosis in OS
(Takeda et al, 2007a). Liver kinase B1 loss has also been associated
with a more aggressive clinical phenotype in KRAS-mutant non-
small-cell lung cancer patients accordingly to preclinical models
(Calles et al, 2015). In addition, knockdown of endogenous LKB1
gives rise to dysregulation of cell polarity and invasive phenotype
of breast cancer cells (Li et al, 2014). Moreover, mice harbouring a
heterozygous germline inactivating LKB1 mutation develop
gastrointestinal polyps, liver neoplasia and later multifocal
osteogenic and osteoblastoma-like tumours (Robinson et al, 2008).
Liver kinase B1 is a serine/threonine kinase, which in humans is
encoded by the LKB1/STK11 gene that regulates cell polarity and
functions as a tumour suppressor (Baas et al, 2003; Partanen et al,
2012). Liver kinase B1 is an upstream kinase of adenine
monophosphate-activated protein kinase (AMPK), a necessary
element in cell metabolism that is required for maintaining energy
homeostasis. Liver kinase B1 is activated allosterically by binding to
the pseudokinase STRAD and the adaptor protein MO25 (Baas
et al, 2003; Boudeau et al, 2003; Hawley et al, 2003; Gaude et al,
2011). The LKB1-STRAD-MO25 heterotrimeric complex repre-
sents the biologically active unit that is capable of phosphorylating
and activating AMPK and at least 12 other kinases that belong to
the AMPK-related kinase family as well as other downstream
targets such as mTOR, S6K, RPS6 and eIF4E (Hawley et al, 2003;
Lizcano et al, 2004; Alexander and Walker, 2011; Hardie and
Alessi, 2013; Patel et al, 2014).
It has been shown previously that sirtuin 1 (SIRT1) antagonises
LKB1-dependent AMPK activation by promoting the deacetyla-
tion, ubiquitination and proteosome-mediated degradation of
LKB1 in a senescence model of primary porcine aortic endothelial
cells (Zu et al, 2010). Sirtuin 1 is a NADþ -dependent deacetylase
protein, which has a role in a wide variety of processes including
stress resistance, metabolism, differentiation and ageing. Sirtuin 1
binds and regulates the activity of several transcription factors
including FOXO1, FOXO3 and FOXO4, HES-1 and PPAR, NF-kB
and PGC1 (Wang et al, 2011; Hori et al, 2013; Lee and Goldberg,
2013). Sirtuin 1 has been shown to interact with and to deacetylate
the p53 tumour suppressor protein (Lain et al, 2008; Yamakuchi
et al, 2008).
Although osteoblastoma-like tumours were developed in LKB1
heterozygous mice, screening 113 OS patients found no LKB1
genetic alterations, and in light of those findings, we investigated
LKB1 expression in OS cases by hypothesising that SIRT1
deacetylase impairs LKB1 protein and provided further informa-
tion into the mechanism of expression loss in those tumours.
MATERIALS AND METHODS
Tumour samples. The tumour samples were obtained from the
Stanmore Musculoskeletal Biobank located in the histopathology
department of The Royal National Orthopaedic Hospital, and the
study was approved by the Cambridgeshire two Research Ethics
Service (reference 09/H0308/165), the UCL Biobank for the Health
and Disease ethics committee (covered by the Human Tissue
Authority licence 12055; project EC17.1).
Cell culture and transfection. The human OS cell lines SaOS2,
HOB, U2OS, MNNG-HOS, HOS, ZK58, KPD, HAL and OSA were
obtained from EuroBoNeT (project no. LSHC-CT-2006-018814;
http://eurobonet.pathobiology.eu/cd/index.php) and grown in
Dulbecco’s modified Eagle’s medium with 10% foetal calf serum
in 5% CO2. All cell lines have been authenticated in http://
www.ncbi.nlm.nih.gov/biosample/ and ensured that they are not
misidentified. The ZK58, KPD, U2OS, OSA, HAL and OST cell
lines were wild type (WT) for TP53, whereas the MNNG-HOS and
HOS cell lines carry TP53 mutations, and SaOS2 has a homozygote
deletion for TP53 (Ottaviano et al, 2010).
For transient transfections, with morpholinos or mimic
microRNAs (miRNA), OS cell lines were transfected in 6-well
plates with Endo-Porter (Gene Tools LLC, Philomath, OR, USA),
Oligofectamine or Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA). For permanent knockdown transfection, the MNNG-HOS
OS cell line, known to express high level of LKB1 (Takeda et al,
2007b), was manipulated using four hairpin clones of the Open
Biosystems (GE Healthcare, Darmacon, Lafayette, CO, USA)
pGIPZ human lentiviral shRNAmir-expressing LKB1-targeting
shRNA (V3LHS 69003). Cell growth was monitored using a live
imaging system, IncuCyte HD (Essen BioScience, Welwyn Garden
City, UK). MCF-7 and HEK293T cells, which express little and
high levels of LKB1, respectively, at the RNA and protein level,
were grown in Dulbecco’s modified Eagle’s medium supplemented
with 10% FBS. For the knocking-in experiment, a pBABE-LKB1
construction was used (Addgene, Cambridge, MA, USA). The
empty backbones were used as a negative control. The vectors were
prepared using Maxiprep Kit (Qiagen, Crawley, UK) according to
the manufacturer’s instructions.
Immunoblotting and immunoprecipitation. Cells were lysed
with RIPA lysis buffer (50mM Tris-HCl (pH 7.5), 200mM NaCl
and 10mM CaCl2, 0.5% NP40) for immunoblotting. The debris
was removed by centrifugation and the supernatant was precleared
with protein G PLUS beads (Santa Cruz, Dallas, TX, USA), and
immunoprecipitated with a rabbit IgG antibody. Precleared lysates
were sequentially incubated overnight at 4 1C (gentle agitation)
with the primary antibody (4 mg (w v 1) for 2 h) and protein G
plus. Immunoprecipitated complexes were resolved by SDS–PAGE
(8% acrylamide) for WB analysis. The gels were stained with anti-
acetyl-lysine antibody, Chip Grade (Abcam, Cambridge, UK). The
density of stained proteins was assayed on immunoblots using
Image J v1.421 (NIH, Bethesda, MD, USA).
Immunohistochemistry and double immunofluorescence label-
ling. Immunofluorescent analysis was performed on rehydrated
paraffin-embedded full tissue sections (3–4mm). The primary
antibodies included anti-SIRT1 (1 : 200, ab7343), anti-LKB1 (1:100,
Ley37D/G6 and ab185734) (Abcam). The conjugated antibodies,
anti-mouse Alexa Fluor-488 and anti-rabbit Alexa Fluor-568
(Molecular Probes, Eugene, OR, USA) were used as secondary
antibodies. Immunohistochemistry was performed as described
previously (Amary et al, 2011). Other antibodies have been listed
in Supplementary Table 1.
Cell cycle analysis. Cell cycle analysis was performed using the
CyAn ADP flow cytometry (Beckman Coulter, High Wycombe,
UK). SaOS2 and HOB cells were seeded in 100mm2 plates to
achieve 60–70% confluency following 24 h. At 2 days after
transfection with morpholino antisense oligos (Gene Tools LLC)
blocking SIRT1 RNA, the cells were harvested, centrifuged and
washed with PBS. After fixation with ice-cold 70% EtOH, they
were incubated in 7-AAD or anti-BrdU-FITC (BD Pharmingen,
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Oxford, UK). Data were analysed by Summit v4.3 (DakoCytoma-
tion, Glostrup, Denmark).
Agilent Human miRNA Microarray V2 and data analysis. Total
RNA was extracted (miRNAeasy Kit, Qiagen Ltd, Crawley, UK)
and the small RNA fraction was assessed for integrity and quality
using Small RNA Kit Lab on Chip (Agilent Technology UK Ltd,
Wokingham, UK). One hundred nanogram of total RNA per
sample was labelled and hybridised to the Agilent Human miRNA
Microarray V2 following the manufacturer’s recommendations
(Agilent Technology). Microarray slides were scanned using an
Agilent Microarray Scanner G2 505B (Agilent Technology) and the
images automatically analysed using Feature Extraction Software,
version 9.5.1.1 (Agilent Technology). miRNA analysis was carried
out using Bioconductor packages for the R statistical programming
language (Gentleman et al, 2004). The (gMedianSignal) back-
ground was subtracted (gBGUsed) and the arrays normalised to
each other using the ’normexp’ function (Ritchie et al, 2007) of the
Limma package. The Limma package was also used for differential
expression and multiple testing was controlled using the false
discovery rate (q-value). The expression patterns were obtained by
hierarchical clustering, performed by the Cluster v.3 program
and visualised by the TreeView v.1.6 software package http://
bonsai.hgc.jp/~mdehoon/software/cluster/software.htm, and their
median presented in a heatmap.
Reverse Transcriptase–quantitative PCR. Complementary DNA
was synthesised using the Superscript III First DNA Kit
(Invitrogen) and used as a template in SYBR Green PCR Master
Mix (Applied Biosystems) to assay LKB1, SIRT1 and SIRT2 mRNA
expression. miRNA expressions were investigated using TaqMan
miRNA Assay Technology (Applied Biosystems). All reactions
were performed in triplicate. The expression of the gene was
quantified using either DCt or 2^(DCt) normalised to internal
controls, RNU66, GAPDH or 18s (Supplementary Table 2).
LKB1 gene analysis. Twenty-one OS samples from different
patients were investigated at the locus of several SNPs along LKB1
gene. The exons 1, 2, 3, 7 and 8 (and the surrounding intron
containing the SNPs) were amplified by PCR (Supplementary
Table 3) and cleaned using the Qiaquick PCR Purification Kit
(Qiagen, Crawley, UK) and analysed by electrophoresis. The status
of five SNPs (Supplementary Table 4) was also assessed by
restriction digestion (Sobottka et al, 2000).
Fluorescence in situ hybridisation (FISH) was performed using
the LKB1 BAC probes generated as described previously (Fernanda
Amary et al, 2014). DNA BAC probes were selected from the RP11
library of the Sanger Institute: RP11-81M8 for LKB1 (Spectrum-
Orange) and RP11-91H11 for the telomeric control (Spectrum-
Green) on chromosome 19 (BACPAC Resource Centre, Oakland,
CA, USA). Both probes were tested on normal cells’ metaphase
spread to ensure that they mapped to the right chromosome. To
assess the FISH analysis, 50 nuclei were counted in each case and
four normal controls were also used to determine the cutoff values
for disomy and copy number loss and gain of LKB1.
Statistical analysis. Statistical significance of growth curves was
assessed using the Mann–Whitney test using the GraphPad Prism
Statistical Software Inc. (GraphPad Software, Inc., La Jolla, CA,
USA). Po0.05 was considered statistically significant. Average
values were expressed as mean±s.d.
RESULTS
LKB1 expression in OSs. Forty-one per cent (106 out of 259) of
informative human OS samples from different patients revealed
loss of LKB1 expression as assessed by immunohistochemistry
(Figure 1A and Supplementary Figure 1). Thirty of these tumours
(random selection) were also analysed for LKB1 expression by WB
and 14 revealed loss of expression (Figure 1B). The immunohis-
tochemistry and WB data of the primary tumours correlated in 28
of 30 cases (94%). The absence of immunoreactivity in 6 of 10 cell
lines (60%) correlated with low or absent detection of LKB1 on WB
(Figure 1C).
Loss of LKB1 and activation of mTOR pathway in OS. Using
IHC we screened for the expression of key molecules in the mTOR
pathway, which could modulate or be modulated by LKB1. The
selected molecules studied and their eventual phosphorylation sites
were (TSC2 and p-TSC2 (Thr1462), mTOR and p-mTOR (Ser2448),
S6K and p-S6K (Thr389), RPS6 and p-RPS6 (Ser235/236). Repre-
sentative positive and negative cases by IHC and positive controls
are presented in Supplementary Figure 2 and a graphical summary
in Figure 1D. We found that LKB1 was not detected in 75 of 133
(56%) of the OS cases showing mTOR pathway activation, whereas
only 16 of 91 (18%) LKB1-negative cases did not show pathway
activation (Figure 1E). Hence, the relative risk of having the
pathway activated was 12.78 times higher if LKB1 was absent (95%
confidence interval). We concluded from the IHC study that the
mTOR pathway is activated in a vast majority of OS cases, as
shown by the phosphorylation of mTOR, TSC2, S6K or RPS6 in
87% of our cohort and pathway activation is associated with
disease progression (Supplementary Figures 2 and 3).
LKB1 genetic alteration. To investigate further the loss of LKB1
protein expression, we looked for potential genetic alterations in
the LKB1 gene. Fluorescence in situ hybridisation of the LKB1
locus gave informative results in 90 OS cases (total 92). Twenty-
eight of 90 (31%) cases were disomic, and 58 of 90 (65%) cases
showed polysomy (between three and seven copies of chromosome
19 (LKB1 locus 19p13.3)). There was no evidence of copy number
loss or gene deletion in the LKB1 locus in any of the 90 cases
(Figure 1F). Expression of LKB1 protein assessed by both IHC and
WB alongside the FISH results showed that 23 out of 32 (72%)
(P¼ 0.002) cases were disomic for LKB1 and lacked LKB1
immunoreactivity (Figure 1G). Hence, the loss of LKB1 protein
expression in OS is rarely, if ever, explained by the loss of LKB1
gene.
We next investigated whether loss of a parental LKB1 allele
could explain the loss of LKB1 protein expression. Twenty-one OS
cases, previously studied for protein expression (immunohisto-
chemistry and WB) were analysed for the status of 12 SNPs in
exons 1, 8 and introns 2, 3, 7, 8 (Supplementary Table 4). Of 20
informative cases, eight failed to reveal any DNA variants. Of the
remaining 12, parental allelic loss at the rs34928889 locus,
accompanied by copy number gain of chromosome 19, was
identified in four cases (33.3% of the 20 cases). Although this
finding could explain a copy neutral loss in LKB1 in these cases
(Supplementary Tables 3 and 4), direct sequencing of exons 1, 4, 5,
6 and 8 of the 20 informative cases failed to detect any genetic
alterations. In addition, no mutations were found in exons 2, 3 and
7 in the four cases presenting loss of a parental allele. Furthermore,
whole-genome sequencing with the Illumina HiSeq Platform
(performed at Sanger Institute as part of an on-going collabora-
tion), on 113 OS cases also showed no significant LKB1 genetic
alterations (data no shown).
LKB1 expression at the transcriptional level. To test whether loss
of LKB1 mRNA level could account for the loss of protein
expression, LKB1 mRNA levels in human OS samples and cell lines
were correlated with their protein levels. The RT–qPCR for LKB1
mRNA level was performed on 11 OS cell lines and 23 OS cases.
All the OS cases expressed detectable and significant LKB1 mRNA
levels compared with the average RNA level of the positive controls
(Jurkat, HF1 cell lines) (Figure 1I), regardless of LKB1 protein
expression levels, analysed by WB and IHC (Figure 1I).
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Figure 1. LKB1 expression and its genetic alterations in osteosarcomas. (A) IHC of LKB1 in two OS with positive immunoreactivity (left) and negative
immunoreactivity (right). (B) Immunoblots of endogenous LKB1 and SIRT1 protein expression in OS tumours (n¼12 cases) normalised to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. HEK293T cells was used as a positive control. (C) Immunoblots on OS cell lines
using anti-LKB1 and SIRT1. Control cell lines HEK-293T (positive for LKB1 expression) and MCF7 and MDA-MB (negative for LKB1) were compared for
LKB1 immunoreactivity in OS cell lines and patient biopsies. (D) Expression of phosphorylated and total protein for mTOR, S6K and RPS6.
(E) Association between LKB1 and mTOR pathway activation in OS. Bar chart representing the LKB1 immunoreactivity compared with the pathway
activation, for Po5 1015 with Wilcoxon’s signed-rank test. (F) FISH for LKB1 locus on tissue microarray (TMA) samples. Copy number loss of LKB1
was defined by a ratio of LKB1 over telomere strictlyo1 in at least 20% of the cells and copy number gain by a ratio strictly over 1 in at least 10% of
the cells. The FISH data has been summarised in a graph. (G) Bar chart represents the correlation between occurrence of chromosome 19 polysomy
and the expression of LKB1 protein in OS patients. *Po0.005 with the one-tailed Fisher’s exact test. (H) Pearson’s correlation between LKB1 and SIRT1
staining intensity in OS immunoblots of 12 samples. The immunoblots were scanned and analysed by Image J and data were plotted to see the
relationship. The expression levels were normalised to the GAPDH and compared with the HEK293T WB bands as a positive control (r¼ 0.086,
Po0.01). (I) RT–qPCR on OS cases with no, low and high protein expression of LKB1 (left graph), also on OS cell lines with no/low and high LKB1
protein expression (right graph). 2^(CT) indicating LKB1 mRNA expression normalised to GAPDH expression, unpaired t-test between the groups,
P40.05, NS¼ no significant. A full colour version of this figure is available at the British Journal of Cancer journal online.
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Figure 2. LKB1 regulation via protein degradation machinery. (A) WB for LKB1 on SaOS2 cells exposed for 8 h with PS-341 (2 or 5 mM) or vehicle,
(B) SaOS2, HOB and U2OS cells were treated (þ ) or not ( ) with sirtinol (50mgml 1) for 24 h and then lysates were immunoblotted for LKB1 and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (C) The SaOS2 cells were transfected with morpholinos targeting SIRT1 isoforms (5 and
10mM) or both (5mM of each) and then blotted for SIRT1 and LKB1 proteins. (D) HOB, SaOS2 and U2OS cell lines were treated either with sirtinol
(50mgml 1) or vehicle control for 24 h. LKB1 was immunoprecipitated (IP) from protein lysates using protein G and the level of acetylated LKB1
were determined using anti-acetyl-lysine in WBs and indicated by arrows. (E) The SaOS2 cell lines were transfected with morpholinos (iso1
(5 nM)þ iso2 (5 nM) or scrambled and stained for LKB1 and SIRT1 for immunofluorescence microscopy. (F) The SaOS2 cells treated either with
sirtinol (50mgml1) or transfected with morpholinos (iso1 (5 nM)þ iso2 (5 nM)) revealed a growth arrest monitored by live cell imaging system.
Statistical significance was accepted at **P-valueo0.05 and *Po0.01. (G) Cell cycle profile for SaOS2 cells, 2 days post-transfection with
morpholinos, using incorporation of propidium iodide (PI) or bromodeoxyuridine (BrdU). Representative flow cytometric data showing the cell
cycle distribution and growth arrest in the G1 phase in SIRT1-suppressed cells. (H) The percentage of BrdU-positive cells was determined by
microscopic observation. BrdU-positive and -negative cells were counted at  200 magnification and at least 200 cells were counted in each slide.
The graph shows the average number of cells from each field (at least n¼10) counted in three independent experiments; the bars represent the
mean. *P-valueo0.05. A full colour version of this figure is available at the British Journal of Cancer journal online.
BRITISH JOURNAL OF CANCER LKB1 regulation in osteosarcoma
402 www.bjcancer.com |DOI:10.1038/bjc.2017.174
LKB1 tumourigenicity in OS. We studied the role of LKB1 in
tumourigenicity by functional approaches. OST, SaOS2 and OSA
cell lines, which express very low levels of the endogenous LKB1
protein, were transfected with pBABE-LKB1 (LKB1-(knock-in) KI)
or empty vector (ET-KI) as control and then studied for Anoikis,
cell survival and proliferation. Although there was no significant
difference in cell cycle profile, consistent reduced growth rate and
increased apoptosis in non-adherent condition was observed in
LKB1-KI cells compared with ET-KI (Supplementary Figure 5).
MTS assay on SaOS2 LKB1-KI cells also showed a decreased
metabolism compared with the ET-KI at different cell densities,
and were statistically significant at days 2 and 3 in the lowest cell
density (P¼ 0.0099 and P¼ 0.023, respectively) and the inter-
mediate cell density (P¼ 0.0034 and P¼ 0.030, respectively). Loss
of LKB1 function was investigated in MNNG-HOS cells known to
express LKB1 at the high level at both mRNA and protein levels.
Cell-based assays on knockdown cells revealed that LKB1-KD cells
gained a growth rate compared with the pGTC-(empty vector) ET
with no difference in cell cycle profile (Figure 3A).
Inverse correlation of LKB1 and SIRT1 expression in OS. We
next tested whether the loss of LKB1 expression in OS could be
brought about through the protein degradation machinery, and
specifically through SIRT1 function. Figures 1B, C and H show the
inverse correlation of LKB1 and SIRT1 expression in OS patients
and OS cell lines. Samples expressing high level of SIRT1 expressed
low amount of LKB1 and, inversely, samples with high LKB1
expression showed a low level of SIRT1 expression y¼  1.4068
xþ 0.3579, R2¼ 0.5744 (Figure 1H). The inverse correlation was
also supported by double-immunofluorescence labelling using
antibodies targeting LKB1 and SIRT1 (Figures 4C and D).
However, no inverse correlation was found at mRNA levels of
SIRT1 and LKB1 in those tumours. Furthermore, in tumours and
OS cell lines with low or high level of LKB1 protein expression,
there was no significant difference in RNA levels (Figure 1I).
SIRT1 regulates LKB1 protein expression. Treatment of SaOS2
cell line with a proteasome inhibitor, PS-341 (MG-341), resulted in
LKB1 protein accumulation, the degradation of which was
protected by the molecule PS-341 (Figure 2A). This was reversed
by treatment with sirtinol, an SIRT1 deacetylase inhibitor, and
morpholino antisense oligonucleotides (Figures 2B and C and
Supplementary Table 5), which was specific for SIRT1 and not
SIRT2 (Supplementary Figure 4). Treatment of the OS cell lines
SaOS2, HOB and U2OS with sirtinol and immunoprecipitation
with the anti-LKB1 antibody SIRT1 exerted a significant effect on
LKB1 acetylation (Figure 2D). Sirtuin 1/LKB1 cell localisations
were studied in SaOS2 (Figure 2E) and HOB cells (data not shown)
post-transfection with morpholinos and control. In addition,
inactivation/suppression of SIRT1 in SaOS2 cells resulted in
growth arrest in the G1 phase because of SIRT1 reduction and
LKB1 accumulation in those cells (Figures 2E–H).
The MNNG-HOS cells were transfected stably with lentivirus to
knockdown LKB1 expression and cell growth was monitored
(Figure 3A). Subsequently, the knocked down LKB1 cells were
treated with morpholinos to suppress SIRT1 expression and the
levels of LKB1 and SIRT1 expression (RNA and protein) were
analysed and compared with the controls (Figures 3B and C). A
significant accumulation of LKB1 protein (100%) (Figure 3B) was
observed in the absence of SIRT1 expression in the MNNG-HOS
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cells, while the LKB1 knockdown MNNG-HOS cells lost their
potential to accumulate LKB1 protein.
miR-204 regulates SIRT1 expression in OS. We analysed the 22
OS cases, characterised for SIRT1 and LKB1 status, for miRNA
expression using Agilent miRNA array in a supervised manner
for SIRT1 target miRNA genes acquired from miRWalk2.0
algorithms (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/)
(Supplementary Table 6). The expression patterns were obtained
and their median presented in a heatmap (Figure 4A). miR-29c,
miR-132 and miR-204, which target SIRT1, were among the
microRNAs differentially and significantly expressed between OS
cases (Figure 4A and Supplementary Table 7). However, RT–qPCR,
for those miRNAs, on OS cases revealed that 72% (14 out of 18) of
OS had relative low expression of miR-204 normalised to RNU66
level. From those samples (n¼ 14), 11 informative cases, 67% (11
out of 14), showed a high level of SIRT1 mRNA expression. In
addition, we found a significant correlation (R2¼ 0.0383) between
the low expression of miR-204 and high SIRT1 expression
(Figure 4B). This finding was in a reverse correlation with LKB1
levels (low level of LKB1) in informative cases (inset in Figure 4B,
Po0.05).
miR-204/SIRT1/LKB1 sequential pathway. Double immuno-
fluorescence staining and WB on informative OS cases showed
that the expression of SIRT1 and LKB1 in protein level had a
reverse correlation. Two cases were selected based on the low
(S7007) and high (S7004) levels of LKB1 expression in IHC and
WB (Figures 4C and D). Fluorescence in situ hybridisation analysis
confirmed trisomy at LKB1 locus in sample S7004 (Figure 4E),
while there was no significant difference in the level of RNA
expression between the two cases. Although in both samples, LKB1
mRNA was found to be expressed at the same level, while SIRT1
mRNA in S7004 was lower than S7007, and this coincided with a
higher expression level of miR-204 in S7004 compared with that in
S7007 (Figure 4F).
As miR-204 appeared to be the most relevant microRNA in this
setting, compared with the data obtained from miR-132 and miR-
29c experiments, we studied the effect of miR-204 in SaOS2 cell
line found to express a low level of miR-204. The cells were
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transfected with mimics of miR-204 and subsequently cell growth
and anchorage-independent growth/colony formation was assessed
(Figures 5A–C). Sirtuin 1 and LKB1 protein expressions were also
analysed and showed almost 50% reduction in SIRT1 protein levels
and double expression of LKB1 in the cells transfected with miR-
204 compared with the scrambled miRNA on day 4 of post-
transfection (Figure 5D).
DISCUSSION
The role of LKB1 in cancer has recently stimulated considerable
interest. Although it has been shown that the somatic inactivation
of LKB1 is associated with the development of cancer in several
tissues (Zhong et al, 2006; Ji et al, 2007; Shorning and Clarke,
2011), the role of LKB1 in OS has not been studied in depth. In this
study, we report the absence of LKB1 expression in 41% of OS,
which was not due to any genetic alterations as previously shown
in concordance with Lorenz et al (2016) and the COSMIC
database, http://www.sanger.ac.uk/genetics/CGP/cosmic/). Analys-
ing LKB1 at the mRNA level and performing miRNA array did not
support the idea of deficiency at the transcriptional level, in spite of
reports showing miRNAs, miR-451 and miR-155, targeting LKB1
mRNA in glioma cells and cervical cancer cells, respectively
(Godlewski et al, 2010; Lao et al, 2014). The absence of LKB1
protein expression in spite of the presence of mRNA implies a
post-translational mechanism. Sirtuin 1 deacetylase have important
roles in many biological pathways, including cancer development
(Sanchez-Cespedes et al, 2002; Ji et al, 2007; Lim, 2007; Deng,
2009; Wingo et al, 2009; Knight and Milner, 2012). Sirtuin 1 can
modulate cell survival by regulating the transcriptional activities of
p53, NF-kB (Yeung et al, 2004), FOXO proteins (Wang et al, 2011)
and p300 (Bouras et al, 2005; Li and Luo, 2011). It has been shown
that SIRT1 inhibition decreases Foxp3 polyubiquitination, thereby
increasing the Foxp3 protein level (van Loosdregt et al, 2011).
Furthermore, our group recently reported that high SIRT1 protein
expression was associated with metastases in Ewing sarcoma and a
poor prognosis (Ban et al, 2014), showing the important role of this
molecule in bone tumours. In addition, here we showed that loss of
LKB1 could induce constitutive mTOR activation, even in the
absence of detection of p-TSC2 (Thr1462), and in vitro gain of LKB1
in OS cell lines shows a tumourigenic function.
We provide evidence via the use of small compound inhibitors
and gene suppression that LKB1 loss is through post-translational
regulation. We found that LKB1 deacetylase by SIRT1 facilitates
LKB1 proteasomal degradation. A mutually exclusive/reverse
expression of SIRT1 and LKB1 protein shown by WB and double
immunofluorescence microscopy also support this finding. There-
fore, it appears that SIRT1 impairs LKB1 protein stability and that
SIRT1 depletion leads to the accumulation of LKB1 in OS cell lines
resulting in growth arrest. In LKB1 knockdown OS cells, LKB1 is
restored by SIRT1 inhibitor or morpholinos, resulting in increased
proliferation. These findings reveal a possible mechanism for the
loss of expression of LKB1 tumour suppressor in OS. This is in
agreement with Zu et al (2010), who showed that SIRT1
antagonises LKB1-dependent AMPK activation by promoting
the deacetylation, ubiquitination and proteosome-mediated
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degradation of LKB1, in a senescence model in primary porcine
aortic endothelial cells (Zu et al, 2010). Recently, it has been
reported that SIRT1 expression prevents adverse arterial remodel-
ling by facilitating HECT and RLD domain-containing E3
ubiquitin protein ligase 2-mediated degradation of acetylated
LKB1 and acetylation at K64, LKB1 showed an enhanced
interaction with SIRT1 (Bai et al, 2016). However, Lan et al,
2008 demonstrated that overexpression of SIRT1 in 293 T cells
diminished acetylation of LKB1 and caused its movement from the
nucleus to the cytoplasm, where LKB1 can associate with the
adaptor proteins, STE20-related adaptor protein and mouse
embryo scaffold protein, resulting in its own activation and
subsequent activation of AMPK pathway (Lan et al, 2008). We
showed here that immunofluorescence colocalisation of LKB1 and
SIRT1 on OS cell lines (SaOS2, HOB, U2OS), treated with sirtinol
or morpholinos, led to the accumulation of LKB1 in the cytoplasm.
We showed that LKB1 was predominantly localised in the
cytoplasm after SIRT1 inhibition. In addition, STRAD always
colocalised with LKB1 in the cytoplasm (data not shown).
Consistent with our results of reverse correlation of SIRT1 and
LKB1 function, it has been shown that metformin, a SIRT1
activator and widely used as an antidiabetes drug, can suppress
memory of hyperglycaemia stress and ROS generation in the
retinas of diabetic animals through the SIRT1/LKB1/AMPK/ROS
pathway (Zheng et al, 2012).
Investigating SIRT1 upstream regulators demonstrated the post-
transcriptional regulation of SIRT1 by miRNAs and RNA-binding
proteins. More than 16 miRNAs have been found in silico and
experimentally to regulate both SIRT1 expression and activity
(Yamakuchi, 2012). Among them are miR-29c, miR-132 and miR-
204, which have been shown to contribute to tumour progression
by downregulating the expression of SIRT1 ( Strum et al, 2009;
Saunders et al, 2010; Zhang et al, 2013; Bae et al, 2014). Performing
mimic studies on miR-204 showed a growth arrest in SaOS2 cells,
which coincided with SIRT1 protein reduction and an accumula-
tion in LKB1 protein expression. These data are in agreement with
Shi et al (2015), showing that miR-204 inhibits proliferation and
epithelial–mesenchymal transition via SIRT1 (Zhang et al, 2013) in
gastric cancer cells. However, miR-204 has other target genes,
which also lead to cell growth arrest (Shi et al, 2014; Yin et al, 2014;
Sun et al, 2015; Wu et al, 2015). All these findings suggest a
sequential regulation between those molecules. Therefore, the low
expression of these miRNAs may contribute to tumour develop-
ment in the context of SIRT1 upregulation and LKB1 down-
regulation in a subset of OS cases.
Despite developing osteoblastic tumours in LKB1þ / mice
(Robinson et al, 2008), we could not find any genetic alterations at
the LKB1 locus in OS, even though OS revealed loss of LKB1
protein expression. Furthermore, we showed that SIRT1 upregula-
tion in OS has a significant correlation with LKB1 loss, and that
SIRT1 suppression revealed a restoration and accumulation of
LKB1 and growth arrest. We also demonstrated a role for miR-204
in the SIRT1/LKB1 pathway, which may explain the loss of LKB1
expression through SIRT1 expression and its potential in arresting
growth and attenuation of anchorage-independent growth in OS
cells. Our findings suggest involvement of sequential regulation of
miR-204-SIRT1-LKB1 in OS development. Therefore, targeting
this pathway may represent a useful therapeutic approach to
control OS growth in those subsets demonstrating loss of LKB1
expression.
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